Do Patients with Advanced NSCLC Doing Well on an Immune Checkpoint Inhibitor Reach a Point of Diminishing Returns after a Fixed Duration of Treatment? (BMIC-008) - 102204

Spotlight
Video

Do Patients with Advanced NSCLC Doing Well on an Immune Checkpoint Inhibitor Reach a Point of Diminishing Returns after a Fixed Duration of Treatment? (BMIC-008)

BeaconMedIC has 40 videos Subscribe Here

Loading........
Description: Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value in continuing an immune checkpoint inhibitor in patients with advanced NSCLC doing well on immunotherapy.
Shared By : BeaconMedIC
Posted on : 09/12/17
Added : 9 months ago
Category : Immunotherapy